This confederation of projects is headed by Mark I. Greene who has been involved in the study of immune regulation and phenotype reversal for over 30 years. The goals of this highly integrated program project are to develop understanding of how the FoxpS proteins exert their biological effects and through this knowledge to develop translationally relevant therapeutics that disable or activate the Foxp3 complex. Although the theme of Foxp3 function resonates in each project, a variety of distinct technologies are actually employed to develop insights into how Foxp3 complexes operate and how to manipulate them, leading to a highly interactive group of experiments that should lead to therapeutics that will reach the clinic within the time frame of this program project. The long-term goals are reiterated in every project and all projects share recurrent themes of Treg phenotype manipulation. The studies to date have already lead to a rational therapeutic for autoimmune conditions that is entering a preliminary clinical trial at the NIH. The goal of Greene's project is to provide basic biochemical information of how the Foxp3 complex binds to chromatin in human cells. This information will be helpful in Andrew Wells's study of mouse chromatin - Foxp3 interactions and will be useful in the creation of transgenic and mutant mice that will help the Hancock project and the Wells project. Human and mouse Foxp3 complexes appear to have differences although both form large ensembles. The intent of Project 1 is to identify individual residues that are acetylated and phosphorylated and subdomains that mediate interactions with other repressive components. This information will provide a framework for Andrew Wells to examine chromatin remodeling events in the mouse and for Wayne Hancock to examine functional relevance in in vivo models.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-SV-I (J2))
Program Officer
Lapham, Cheryl K
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
Schools of Medicine
United States
Zip Code
Liu, Yujie; Wang, Liqing; Han, Rongxiang et al. (2014) Two histone/protein acetyltransferases, CBP and p300, are indispensable for Foxp3+ T-regulatory cell development and function. Mol Cell Biol 34:3993-4007
Xiao, Yan; Nagai, Yasuhiro; Deng, Guoping et al. (2014) Dynamic interactions between TIP60 and p300 regulate FOXP3 function through a structural switch defined by a single lysine on TIP60. Cell Rep 7:1471-80
Nagai, Y; Limberis, M P; Zhang, H (2014) Modulation of Treg function improves adenovirus vector-mediated gene expression in the airway. Gene Ther 21:219-24
Akimova, T; Xiao, H; Liu, Y et al. (2014) Targeting sirtuin-1 alleviates experimental autoimmune colitis by induction of Foxp3+ T-regulatory cells. Mucosal Immunol 7:1209-20
Wang, Liqing; Liu, Yujie; Beier, Ulf H et al. (2013) Foxp3+ T-regulatory cells require DNA methyltransferase 1 expression to prevent development of lethal autoimmunity. Blood 121:3631-9
Wang, Liqing; Liu, Yujie; Han, Rongxiang et al. (2013) Mbd2 promotes foxp3 demethylation and T-regulatory-cell function. Mol Cell Biol 33:4106-15
Du, Taofeng; Nagai, Yasuhiro; Xiao, Yan et al. (2013) Lysosome-dependent p300/FOXP3 degradation and limits Treg cell functions and enhances targeted therapy against cancers. Exp Mol Pathol 95:38-45
Liu, Yujie; Wang, Liqing; Predina, Jarrod et al. (2013) Inhibition of p300 impairs Foxp3? T regulatory cell function and promotes antitumor immunity. Nat Med 19:1173-7
Akimova, Tatiana; Beier, Ulf H; Liu, Yujie et al. (2012) Histone/protein deacetylases and T-cell immune responses. Blood 119:2443-51
Zhang, Hongtao; Xiao, Yan; Zhu, Zhiqiang et al. (2012) Immune regulation by histone deacetylases: a focus on the alteration of FOXP3 activity. Immunol Cell Biol 90:95-100

Showing the most recent 10 out of 23 publications